195 related articles for article (PubMed ID: 22716147)
1. Anandamide dysfunction in prodromal and established psychosis.
Leweke FM
Curr Pharm Des; 2012; 18(32):5188-93. PubMed ID: 22716147
[TBL] [Abstract][Full Text] [Related]
2. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis.
Koethe D; Giuffrida A; Schreiber D; Hellmich M; Schultze-Lutter F; Ruhrmann S; Klosterkötter J; Piomelli D; Leweke FM
Br J Psychiatry; 2009 Apr; 194(4):371-2. PubMed ID: 19336792
[TBL] [Abstract][Full Text] [Related]
3. Association of anandamide with altered binocular depth inversion illusion in schizophrenia.
Reuter AR; Bumb JM; Mueller JK; Rohleder C; Pahlisch F; Hanke F; Arens E; Leweke FM; Koethe D; Schwarz E
World J Biol Psychiatry; 2017 Sep; 18(6):483-488. PubMed ID: 27734750
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms.
Morgan CJ; Page E; Schaefer C; Chatten K; Manocha A; Gulati S; Curran HV; Brandner B; Leweke FM
Br J Psychiatry; 2013 May; 202(5):381-2. PubMed ID: 23580381
[TBL] [Abstract][Full Text] [Related]
5. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.
Leweke FM; Giuffrida A; Koethe D; Schreiber D; Nolden BM; Kranaster L; Neatby MA; Schneider M; Gerth CW; Hellmich M; Klosterkötter J; Piomelli D
Schizophr Res; 2007 Aug; 94(1-3):29-36. PubMed ID: 17566707
[TBL] [Abstract][Full Text] [Related]
6. Familial abnormalities of endocannabinoid signaling in schizophrenia.
Koethe D; Pahlisch F; Hellmich M; Rohleder C; Mueller JK; Meyer-Lindenberg A; Torrey EF; Piomelli D; Leweke FM
World J Biol Psychiatry; 2019 Feb; 20(2):117-125. PubMed ID: 29521179
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide.
Fowler CJ
Fundam Clin Pharmacol; 2006 Dec; 20(6):549-62. PubMed ID: 17109648
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids and psychosis.
D'Souza DC
Int Rev Neurobiol; 2007; 78():289-326. PubMed ID: 17349865
[TBL] [Abstract][Full Text] [Related]
9. Elevated endogenous cannabinoids in schizophrenia.
Leweke FM; Giuffrida A; Wurster U; Emrich HM; Piomelli D
Neuroreport; 1999 Jun; 10(8):1665-9. PubMed ID: 10501554
[TBL] [Abstract][Full Text] [Related]
10. Anandamide is involved in appetite-related amygdala hyperactivations in schizophrenia patients treated with olanzapine: a functional magnetic resonance imaging study.
Potvin S; Lungu OV; Stip E
J Clin Psychopharmacol; 2015 Feb; 35(1):82-3. PubMed ID: 25370126
[No Abstract] [Full Text] [Related]
11. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy.
Potvin S; Kouassi E; Lipp O; Bouchard RH; Roy MA; Demers MF; Gendron A; Astarita G; Piomelli D; Stip E
J Psychopharmacol; 2008 May; 22(3):262-9. PubMed ID: 18308802
[TBL] [Abstract][Full Text] [Related]
12. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans.
Thieme U; Schelling G; Hauer D; Greif R; Dame T; Laubender RP; Bernhard W; Thieme D; Campolongo P; Theiler L
Drug Test Anal; 2014; 6(1-2):17-23. PubMed ID: 24424856
[TBL] [Abstract][Full Text] [Related]
13. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid.
Koethe D; Schreiber D; Giuffrida A; Mauss C; Faulhaber J; Heydenreich B; Hellmich M; Graf R; Klosterkötter J; Piomelli D; Leweke FM
J Neural Transm (Vienna); 2009 Mar; 116(3):301-5. PubMed ID: 19137236
[TBL] [Abstract][Full Text] [Related]
14. Plant cannabinoids: a neglected pharmacological treasure trove.
Mechoulam R
Br J Pharmacol; 2005 Dec; 146(7):913-5. PubMed ID: 16205721
[TBL] [Abstract][Full Text] [Related]
15. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
Roser P; Vollenweider FX; Kawohl W
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
[TBL] [Abstract][Full Text] [Related]
16. Biphasic effects of anandamide on behavioural responses: emphasis on copulatory behaviour.
Rodríguez-Manzo G; Canseco-Alba A
Behav Pharmacol; 2015 Sep; 26(6):607-15. PubMed ID: 26226145
[TBL] [Abstract][Full Text] [Related]
17. Natural and synthetic endocannabinoids and their structure-activity relationships.
Palmer SL; Khanolkar AD; Makriyannis A
Curr Pharm Des; 2000 Sep; 6(13):1381-97. PubMed ID: 10903399
[TBL] [Abstract][Full Text] [Related]
18. Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids.
Appiah-Kusi E; Wilson R; Colizzi M; Foglia E; Klamerus E; Caldwell A; Bossong MG; McGuire P; Bhattacharyya S
Psychol Med; 2020 Aug; 50(11):1862-1871. PubMed ID: 31422779
[TBL] [Abstract][Full Text] [Related]
19. An Introduction to the Endogenous Cannabinoid System.
Lu HC; Mackie K
Biol Psychiatry; 2016 Apr; 79(7):516-25. PubMed ID: 26698193
[TBL] [Abstract][Full Text] [Related]
20. Cannabis: discrimination of "internal bliss"?
Wiley JL
Pharmacol Biochem Behav; 1999 Oct; 64(2):257-60. PubMed ID: 10515300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
